Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Forecast
ZNTL analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.45 / 5 from 11 analysts
- Price target
- $7.44 average of analyst targets
- Upside to target
- +249.5% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.58
- 52-week range
- $1.28 – $6.61
ZNTL analyst ratings
11 analystsNumber of analysts at each rating.
ZNTL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ZNTL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.53 | −$0.63 | −$0.45 | −$0.37 | −44.0% | 7 |
| Current fiscal year (2026) | −$1.99 | −$2.39 | −$1.37 | −$1.80 | −10.5% | 8 |
| Next fiscal year (2027) | −$1.78 | −$2.76 | −$1.27 | −$1.99 | +10.4% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ZNTL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $9.8M | $0 | $45.3M | 0.0% | 10 |
ZNTL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ZNTL revenue: reported and forecast
ZNTL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.49 | −$0.58 | −$0.58 | −$0.55 | −$0.53 | +9.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.74 | −$2.11 | −$2.11 | −$2.02 | −$1.99 | +14.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.56 | −$1.80 | −$1.81 | −$1.82 | −$1.78 | +14.5% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ZNTL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ZNTL beat in 7 of 12.
What analysts expect from ZNTL
11 analysts cover Zentalis Pharmaceuticals; their consensus rating is buy (4.45 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.44, 249.5% above the latest close of $2.13. Analysts expect earnings of −$1.99 per share for 2026, −10.5% from a year earlier. For 2027 the average estimate is −$1.78 per share on revenue of $9.8 million. Zentalis Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: ZNTL income statement, ZNTL key metrics, ZNTL chart. See the ZNTL stock overview for the latest quote and news.
ZNTL forecast FAQ
What is Zentalis Pharmaceuticals's price target?
The average analyst price target for Zentalis Pharmaceuticals is $7.44, 249.5% above the latest close of $2.13.
Is Zentalis Pharmaceuticals a buy, hold or sell?
Of 11 analysts covering Zentalis Pharmaceuticals, 8 rate it a strong buy, 0 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Zentalis Pharmaceuticals's EPS forecast?
Analysts forecast −$1.99 per share for 2026 (range −$2.39 to −$1.37); for 2027 the estimate is −$1.78.
When does Zentalis Pharmaceuticals report earnings?
Zentalis Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.58.
Does Zentalis Pharmaceuticals usually beat earnings estimates?
Zentalis Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.